Methods for treating metastatic stage prostate cancer
AssigneeFerring International SA
InventorBo-Eric PERSSON
Life of this patent
Estimating the term…
Abstract
The invention provides methods and dosing regimens for eating metastatic stage prostate cancer in a subject using degarelix, as well as related methods of using degarelix in a subject identified as having metastatic stage prostate cancer, and methods of using degarelix to prevent or delay the progression of locally advanced prostate cancer.
Claims35
A method of treating metastatic stage prostate cancer in a subject comprising:
- identifying a subject with metastatic stage prostate cancer;
- administering an initial dose of degarelix of 160 to 320 mg to the subject;
- and
- administering a maintenance dose of degarelix of 60 to 160 mg to the subject once every 20 to 36 days thereafter,
- thereby treating metastatic stage prostate cancer in the subject.
A method of treating metastatic stage prostate cancer in a subject comprising:
- identifying a subject with metastatic stage prostate cancer;
- administering an initial dose of degarelix of about 240 mg to the subject;
- and
- administering a maintenance dose of degarelix of 80 mg to the subject once every approximately 28 days thereafter,
- thereby treating metastatic stage prostate cancer in the subject.
A method of treating prostate cancer in a subject comprising:
- testing the prostate-specific antigen (PSA) of a potential subject;
- selecting the potential subject for treatment if the subject's PSA level is greater than or equal to 50 ng/mL;
- administering an initial dose of degarelix of 160 to 320 mg to the subject;
- and
- administering a maintenance dose of degarelix of 60 to 160 mg to the subject once every 20 to 36 days thereafter,
- thereby treating prostate cancer in the subject.
A method of using degarelix for the treatment of metastatic stage prostate cancer in a subject comprising:
- identifying a subject with metastatic stage prostate cancer;
- administering an initial dose of degarelix of 160 to 320 mg to the subject;
- and
- administering a maintenance dose of degarelix of 60 to 160 mg to the subject once every 20 to 36 days thereafter,
- thereby using degarelix for the treatment of metastatic stage prostate cancer.
A method of using degarelix to prevent or delay the progression of localized or locally advanced prostate cancer to metastatic stage prostate cancer in a subject comprising:
- identifying a subject with localized or locally advanced prostate cancer;
- administering an initial dose of degarelix of 160 to 320 mg to the subject;
- and
- administering a maintenance dose of degarelix of 60 to 160 mg to the subject once every 20 to 36 days thereafter,
- thereby using degarelix for the prevention of the progression of localized or locally advanced prostate cancer to metastatic stage prostate cancer in the subject.
Dependencies are inferred from the claim text.